公开(公告)号：US20230010501A1

公开(公告)日：2023-01-12

申请号：US17858869

申请日：2022-07-06

申请人： Therapeutic Solutions International, Inc.

发明人： Thomas E. Ichim ,  Timothy G. Dixon ,  James Veltmeyer ,  Kalina O'Connor

IPC分类号： A61K35/15

摘要： Disclosed are means, methods and compositions of matter for treatment Parkinson's Disease through concurrent immune modulation and regenerative means. In one embodiment Parkinson's Disease is treated by augmentation of T regulatory cell numbers and/or activity while concurrently providing regenerative cells such as mesenchymal stem cells, and/or dopamine secreting cells. In one embodiment administration of immunoglobulins such as IVIG together with low dose interleukin-2 and/or low dose naltrexone is disclosed as a preparatory means prior to administration of therapeutic cells such as stem cells. Other therapeutic means utilized in an adjuvant manner are also provided for hormonal rebalancing, transcranial magnetic stimulation, and deep brain stimulation.

公开(公告)号：US20230000909A1

公开(公告)日：2023-01-05

申请号：US17756617

申请日：2020-11-26

申请人： Cell Guidance Systems Limited

发明人： Michael Howard JONES ,  Christian PERNSTICH ,  Astrid WENDLER ,  Nicholas JAMES

IPC分类号： A61K35/15 ,  A61P35/00 ,  C07K14/435

摘要： The invention relates to self-assembling proteins that are capable of being used to deliver cargo proteins to phagocytic cells, and the subsequent delivery and utility of these self-assembling proteins by the phagocytic cells at sites of disease. In particular, the invention relates inter alia to phagocytic cells comprising polyhedrin protein crystals, wherein the crystals themselves encapsulate therapeutic and/or diagnostic proteins. The invention also provides therapies using these cells.

公开(公告)号：US20230000908A1

公开(公告)日：2023-01-05

申请号：US17642320

申请日：2020-09-10

申请人： OHIO STATE INNOVATION FOUNDATION

发明人： Yizhou DONG ,  Xucheng HOU ,  Xinfu ZHANG

IPC分类号： A61K35/15 ,  C12N9/64 ,  C07K7/08 ,  A61P31/04 ,  A61K9/51

摘要： The present disclosure relates to antigen presenting cells and uses thereof for treating sepsis. In some aspects, disclosed herein is an antigen presenting cell, comprising: a lipid-based nanoparticle, comprising: a recombinant polynucleotide, comprising: a first nucleic acid encoding an antimicrobial peptide; a second nucleic acid encoding cathepsin B; and a third nucleic acid encoding a linker; and a vitamin-lipid.

公开(公告)号：US20220409660A1

公开(公告)日：2022-12-29

申请号：US17809737

申请日：2022-06-29

申请人： UNIST (ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY) ,  SUPINE THERAPEUTICS CO., LTD.

发明人： Jeong Beom KIM ,  Hyun Ah LEE

IPC分类号： A61K35/15 ,  C12N5/0786 ,  G01N33/50 ,  A61P37/00 ,  A61P1/00

摘要： Provided are a composition and method for inducing direct conversion from a somatic cell into a myeloid cell and use thereof, in which differentiation from a somatic cell into a myeloid cell can be efficiently induced through the expression of a single direct conversion inducer without undergoing the pluripotency stage of induced pluripotent stem cells, and thus, the composition can be widely used as an effective preventive and therapeutic agent for immune diseases.

公开(公告)号：US11471530B2

公开(公告)日：2022-10-18

申请号：US16389358

申请日：2019-04-19

申请人： SNIPR Technologies Limited

发明人： Jasper Clube

IPC分类号： A61K39/00 ,  A61K39/38 ,  A61K39/02 ,  A61K39/09 ,  A61K39/085 ,  A61K39/10 ,  A61K39/08 ,  A61K39/102 ,  A61K39/118 ,  A61K39/395 ,  A61K35/15 ,  A61K35/17 ,  A61K31/7105 ,  A61P37/00 ,  A61P35/00

摘要： The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.

公开(公告)号：US20220325244A1

公开(公告)日：2022-10-13

申请号：US17729681

申请日：2022-04-26

申请人： Asgard Therapeutics AB

发明人： Carlos Filipe Ribeiro Lemos Pereira ,  Cristiana Ferreira Pires ,  Fábio Alexandre Fiúza Rosa

IPC分类号： C12N5/0784 ,  A61K35/15 ,  A61K45/06 ,  C12N15/86

摘要： The present disclosure relates to compositions, nucleic acid constructs, methods and kits thereof for cell induction or reprogramming cells to the dendritic cell state or antigen presenting cell state, based, in part, on the surprisingly effect described herein of novel use and combinations of transcription factors that permit induction or reprogramming of differentiated or undifferentiated cells into dendritic cells or antigen presenting cells. Such compositions, nucleic acid constructs, methods and kits can be used for inducing dendritic cells in vitro, ex vivo, or in vivo, and these induced dendritic cells or antigen presenting cells can be used for immunotherapy applications.

公开(公告)号：US20220324866A1

公开(公告)日：2022-10-13

申请号：US17127297

申请日：2020-12-18

申请人： GILEAD SCIENCES, INC. ,  CARNA BIOSCIENCES, INC.

发明人： Masaaki SAWA ,  Mai ARAI ,  Ryoko NAKAI ,  Hirokazu MATSUMOTO ,  Catherine PUGH ,  Eric HU ,  Juan GUERRERO ,  Jesse JACOBSEN ,  Jonathan William MEDLEY ,  Jie XU ,  Latesh LAD ,  Leena PATEL ,  Michael GRAUPE ,  Qingming ZHU ,  Stephen HOLMBO ,  Tetsuya KOBAYASHI ,  Will WATKINS ,  Yasamin MOAZAMI ,  Suet C. YEUNG ,  Julian A. CODELLI ,  Heath A. WEAVER

IPC分类号： C07D487/04 ,  C07D519/00 ,  A61K31/519 ,  A61K31/538 ,  A61K31/55 ,  A61K31/395 ,  A61K31/695 ,  C07F7/18 ,  A61K31/5377 ,  A61K31/553 ,  A61K45/06 ,  A61K39/395 ,  A61K31/704 ,  A61K31/7068 ,  A61K35/17 ,  A61K35/15

摘要： The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

公开(公告)号：US20220323493A1

公开(公告)日：2022-10-13

申请号：US17843643

申请日：2022-06-17

申请人： The General Hospital Corporation

发明人： Mark C. Poznansky ,  Jeffrey A. Gelfand

IPC分类号： A61K35/15 ,  A61P35/00 ,  A61K39/00 ,  A61K45/06 ,  C07K14/47 ,  C07K16/30 ,  C12N5/0784

摘要： This disclosure is directed to methods of preparing dendritic cells or other CD40 bearing antigen-presenting cells and methods of treating cancer by using the dendritic cells or other antigen-presenting cells in combination with anti-chemorepellant agents. This disclosure is further directed to methods of preparing T cells and methods of treating cancer, by activated T cells optionally in combination with anti-chemorepellant agents. The antigen presenting cells of the disclosure are activated by incubation with cancer cells and fusion proteins. The T cells of the disclosures are activated by incubation with activated antigen-presenting cells that were activated by incubation with cancer cells and a fusion protein. In particular, the fusion protein comprises an antigen-binding domain, e.g., an antibody or antibody fragment, and a stress protein domain.

公开(公告)号：US11466053B2

公开(公告)日：2022-10-11

申请号：US16417588

申请日：2019-05-20

申请人： BGI SHENZHEN

发明人： Yunxia Tang ,  Bo Li ,  Yong Hou ,  Shuntao Luo ,  Ying Huang ,  Geng Liu ,  Dongli Li ,  Xiumei Lin

IPC分类号： C07K7/06 ,  A61P35/00 ,  A61K35/15 ,  A61K39/00 ,  G01N33/574 ,  G01N33/68 ,  C12N15/09 ,  A61K38/00 ,  C07K7/00 ,  C07K16/00

摘要： Provided are a polypeptide and nucleic acid for encoding the polypeptide, a nucleic-acid construct, an expression vector, and a host cell containing the nucleic acid, an antigen-presenting cell presenting the polypeptide on the surface of the cell, and immune effector cell thereof, a pharmaceutical composition containing the polypeptide, a vaccine containing the nucleic acid, the nucleic acid construct, the expression vector, the host cell, the antigen-presenting cell, and the immune effector cell, and an antibody recognizing the polypeptide. Also provided is a therapeutic method using the polypeptide, the nucleic acid, the pharmaceutical composition, the vaccine, and the antibody. Also provided are a diagnosis method and diagnosis apparatus for detecting the described polypeptide. Also provided is an application of the polypeptide in preparing a vaccine, a tumor diagnosis kit, or a pharmaceutical composition, and an application of the polypeptide or the nucleic acid as a test target in tumor diagnosis.

公开(公告)号：US20220306978A1

公开(公告)日：2022-09-29

申请号：US17702658

申请日：2022-03-23

申请人： Terumo BCT, Inc.

发明人： Mark E. Jones ,  Dalip Sethi ,  Dennis J. Hlavinka ,  Thomas J. Felt

IPC分类号： C12M1/12 ,  A61K35/15 ,  C12M3/00 ,  C12M1/10 ,  C12N5/00 ,  C12N5/0789

摘要： Implementations are described that relate to methods and systems for growing cells in a hollow fiber bioreactor. In implementations, the cells may be exposed to a number of growth factors including a combination of recombinant growth factors. In other implementations, the cells may be grown in co-culture with other cells, e.g., hMSC's. In implementations, the cells may include CD34+ cells. A coated membrane includes a membrane having a first coating configured to promote cellular adhesion to the membrane and a second coating that includes a soluble protein moiety.